Anna Biosciences

Anna Biosciences is a private biotechnology drug discovery company developing immunotherapy-based medicines through its Syntem Platform. The platform uses proprietary multi-specific small molecules, described as covalent immune recruiters, to create "synthetic immunity" by chemically engaging immune components with diseased cells or viral targets. The company’s stated focus areas include virology, immuno-oncology, and neurodegenerative diseases, with early applications highlighted in COVID-19 and cancer. Anna Biosciences appears to operate as an early-stage platform biotech rather than a clinical-stage developer, and public information indicates its programs remain preclinical. The company emphasizes decentralized partnerships to advance therapeutic development.